Oral viscous mometasone is an effective treatment for eosinophilic esophagitis
J Allergy Clin Immunol Pract
.
2020 Mar;8(3):1107-1109.
doi: 10.1016/j.jaip.2019.08.042.
Epub 2019 Sep 12.
Authors
Erin Phillips Syverson
1
,
Elizabeth Hait
1
,
Douglas R McDonald
2
,
Eitan Rubinstein
1
,
Jeffrey D Goldsmith
3
,
Peter D Ngo
1
,
Paul D Mitchell
4
,
John J Lee
5
Affiliations
1
Division of Gastroenterology and Nutrition, Boston Children's Hospital, Harvard Medical School, Boston, Mass.
2
Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass.
3
Department of Pathology, Boston Children's Hospital, Boston, Mass.
4
Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, Mass.
5
Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass. Electronic address: john.lee@childrens.harvard.edu.
PMID:
31521829
DOI:
10.1016/j.jaip.2019.08.042
No abstract available
MeSH terms
Budesonide
Eosinophilic Esophagitis* / drug therapy
Humans
Mometasone Furoate / therapeutic use
Treatment Outcome
Substances
Mometasone Furoate
Budesonide